Content about Hepatitis C

July 6, 2011

Pharmacy benefit manager Medco Health Solutions’ specialty pharmacy division, Accredo Health Group, has managed to drive down costs for treating hepatitis C by an average of $13,000 per patient, the company said Tuesday.

FRANKLIN LAKES, N.J. — Pharmacy benefit manager Medco Health Solutions’ specialty pharmacy division, Accredo Health Group, has managed to drive down costs for treating hepatitis C by an average of $13,000 per patient, the company said Tuesday.

Medco said Accredo had been successful in using genotype information to identify patients who only may need 24 weeks of therapy, as opposed to 48 weeks, thus reducing costs.

June 16, 2011

Specialty pharmacy provider Axium Healthcare Pharmacy has introduced two recently approved hepatitis C drugs to its HepVisions therapy management program, the company said Thursday.

LAKE MARY, Fla. — Specialty pharmacy provider Axium Healthcare Pharmacy has introduced two recently approved hepatitis C drugs to its HepVisions therapy management program, the company said Thursday.

Axium announced the addition of Merck ’s Victrelis (boceprevir) and Vertex Pharmaceuticals’ Incivek (telaprevir) to the program, through which it provides comprehensive compliance support, patient education, side effect management, clinical interventions and communication with the patient and physician.

June 3, 2011

CVS Caremark is enhancing its hepatitis C patient support program following the recent Food and Drug Administration approval of two new add-on therapies for hepatitis C, the company announced on Friday.

WOONSOCKET, R.I. — CVS Caremark is enhancing its hepatitis C patient support program following the recent Food and Drug Administration approval of two new add-on therapies for hepatitis C, the company announced on Friday.

May 23, 2011

The Food and Drug Administration has approved a treatment for hepatitis C made by Vertex Pharmaceuticals, the agency said Monday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a treatment for hepatitis C made by Vertex Pharmaceuticals, the agency said Monday.

The FDA approved Incivek (telaprevir) to treat adults with chronic hepatitis C infection, particularly those who either have not received interferon-based drug therapy or who have not responded to prior therapies. The drug is approved for use with therapies that include ribavirin and peginterferon alfa.

May 23, 2011

The $290 billion that poor medication adherence costs the U.S. economy every year cuts across every imaginable disease state, but one in which it can be particularly problematic is mental health.


The $290 billion that poor medication adherence costs the U.S. economy every year cuts across every imaginable disease state, but one in which it can be particularly problematic is mental health.


May 16, 2011

The Food and Drug Administration has approved a new treatment for chronic hepatitis C, the agency said Friday.

SILVER SPRING, Md.— The Food and Drug Administration has approved a new treatment for chronic hepatitis C, the agency said Friday.

The FDA announced the approval of Merck’s Victrelis (boceprevir) for patients with the disease. The drug is designed for patients who still have some liver function and have not previously received treatment for chronic hepatitis C infection or have failed previous treatments. The drug is approved for use in combination with the generic drug ribavirin and pegylated interferons, biotech drugs used for treating the disease.

May 9, 2011

Drug maker Merck announced that it has kicked off an initiative that includes a wide range of public education and patient support programs, as well as research efforts to help improve care for people living with chronic hepatitis C virus infections.

WHITEHOUSE STATION, N.J. — Drug maker Merck announced that it has kicked off an initiative that includes a wide range of public education and patient support programs, as well as research efforts to help improve care for people living with chronic hepatitis C virus infections.

Merck's Hope Against Hepatitis C initiative includes a variety of public-private partnerships, educational programs and collaborative research efforts aimed at supporting the hepatitis C community.

April 12, 2011

Medication adherence among hepatitis C patients may improve when patients take antidepressants, according to a new analysis by pharmacy benefit manager Medco Health Solutions presented Monday at the International Conference on Viral Hepatitis.

BALTIMORE — Medication adherence among hepatitis C patients may improve when patients take antidepressants, according to a new analysis by pharmacy benefit manager Medco Health Solutions presented Monday at the International Conference on Viral Hepatitis.

January 20, 2011

The Food and Drug Administration and Health Canada have granted priority review to a drug for treating hepatitis C.

CAMBRIDGE, Mass. — The Food and Drug Administration and Health Canada have granted priority review to a drug for treating hepatitis C.

Vertex Pharmaceuticals announced Thursday that the two agencies had given the designation to telaprevir for treating patients with chronic infections.

November 4, 2010

An investigative treatment for hepatitis C got strong results in patients who had failed previous...

BOSTON An investigative treatment for hepatitis C got strong results in patients who had failed previous treatments or who were new to treatment, according to results of a late-stage clinical trial program announced this week.

October 31, 2010

Drug makers Valeant Pharmaceuticals International and Kadmon Pharmaceuticals will collaborate to develop antiviral drugs for...

October 7, 2010

Swiss drug maker Roche has bought the rights to an investigative treatment for hepatitis C,...

BASEL, Switzerland Swiss drug maker Roche has bought the rights to an investigative treatment for hepatitis C, Roche said.

 

The company announced Thursday that it had purchased global development and commercialization rights to the drug RG7227/ITMN-191 (danoprevir) from InterMune for $175 million.

 

 

Roche said the drug had shown promise in preclinical and early clinical development. The two companies have been developing the drug since 2006.

 

September 27, 2010

The Hart-Scott-Rodino waiting period for Bristol-Myers Squibb’s acquisition of Seattle-based biotech company ZymoGenetics has expired,...

NEW YORK The Hart-Scott-Rodino waiting period for Bristol-Myers Squibb’s acquisition of Seattle-based biotech company ZymoGenetics has expired, enabling Bristol’s acquisition to go through, the drug maker said Tuesday.

 

The drug maker announced the deal to acquire ZymoGenetics for $885 million, or $9.75 per share, earlier this month.

 

 

September 21, 2010

Merck is expanding its patient assistance program, the drug maker said Wednesday....

WHITEHOUSE STATION, N.J. Merck is expanding its patient assistance program, the drug maker said Wednesday.

September 7, 2010

Bristol-Myers Squibb will acquire Seattle-based biotech ZymoGenetics, Bristol said Wednesday....

SEATTLE Bristol-Myers Squibb will acquire Seattle-based biotech ZymoGenetics, Bristol said Wednesday.

 

The New York-based drug maker will acquire ZymoGenetics for $885 million, or $9.75 per share. The boards of both companies approved the deal unanimously.

 

 

The buyout gives Bristol ownership of Recothrom, used to control bleeding during surgical procedures, pegylated-interferon lambda, an investigational treatment for hepatitis C in mid-stage clinical trials, and IL-21, a treatment for melanoma also in mid-stage trials.

August 11, 2010

An investigational drug made by Pharmasset for treating hepatitis C will get expedited review from...

August 8, 2010

An investigational drug in late-stage clinical trials increased the cure rate in patients with hepatitis...

June 24, 2010

The Food and Drug Administration has approved a new rapid blood test for detecting hepatitis...

June 9, 2010

Idenix Pharmaceuticals has started a proof-of-concept study of an investigational drug for hepatitis C currently...

May 25, 2010

A majority of people taking an investigational treatment for hepatitis C were cured after taking...

March 18, 2010

“Systemic underfunding” at the Centers for Disease Control and Prevention’s Division of Viral Hepatitis puts...

WASHINGTON “Systemic underfunding” at the Centers for Disease Control and Prevention’s Division of Viral Hepatitis puts the health of millions of Americans with viral hepatitis at risk, a group of organizations focused on the disease said this week.

March 1, 2010

The market for hepatitis C drugs could get a boost if a clinical trial program...

January 10, 2010

The independent nonprofit partner of the Centers for Disease Control and Prevention and the CDC's...

September 10, 2007

The Body Shop founder Anita Roddick, who used her cosmetics company to help communicate human...